{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:55:25Z","timestamp":1795096525698,"version":"4.10.2"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R00CA240689"],"award-info":[{"award-number":["R00CA240689"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5U24 CA264006"],"award-info":[{"award-number":["5U24 CA264006"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["K08DE029503"],"award-info":[{"award-number":["K08DE029503"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["R00DE031372"],"award-info":[{"award-number":["R00DE031372"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-24-1322538-01-IBCD"],"award-info":[{"award-number":["RSG-24-1322538-01-IBCD"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"VeloSano8"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Despite the promise of immune checkpoint blockade (ICB) in head and neck squamous cell carcinoma (HNSCC), mediators of response are poorly understood. To address this, here we analyzed oropharyngeal HNSCCs treated with neoadjuvant durvalumab (anti-PDL1) alone or in combination with tremelimumab (anti-CTLA4) from the CIAO clinical trial (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03144778\" ext-link-type=\"uri\">NCT03144778<\/jats:ext-link>\n                    ). We found that only the total abundance of intratumoral bacteria predicted ICB response, which was validated in multiple independent cohorts. High intratumoral bacteria abundance was associated with an immunosuppressive tumor microenvironment, characterized by an accumulation of neutrophils coupled with depletion of T cells and other adaptive immune cells. Experimental elevation or reduction in intratumoral bacteria abundance in orthotopic models of HNSCC in female mice recapitulated immunological associations observed in participant tumors. Increasing intratumoral bacteria abundance was sufficient to induce resistance to anti-PDL1 ICB, irrespective of bacterial species tested. Together, these findings demonstrate that high intratumoral bacteria abundance is a key suppressor of antitumor immunity and promotes immunotherapy resistance.\n                  <\/jats:p>","DOI":"10.1038\/s43018-025-01067-1","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T10:01:58Z","timestamp":1767348118000},"page":"80-97","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Intratumoral bacteria are immunosuppressive and promote immunotherapy resistance in head and neck squamous cell carcinoma"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4618-6659","authenticated-orcid":false,"given":"Natalie L.","family":"Silver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5460-860X","authenticated-orcid":false,"given":"Travis D.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Altemus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3261-140X","authenticated-orcid":false,"given":"Tyler","family":"Alban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Noel-Romas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4104-5876","authenticated-orcid":false,"given":"Vladimir","family":"Makarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9802-4937","authenticated-orcid":false,"given":"David J. H.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shwetha V.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akeem","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2686-7721","authenticated-orcid":false,"given":"Rehan","family":"Akbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Burgener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1366-0393","authenticated-orcid":false,"given":"Mohammed","family":"Dwidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9427-0743","authenticated-orcid":false,"given":"Neil","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Sikora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5309-3197","authenticated-orcid":false,"given":"Elias J.","family":"Sayour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apollo","family":"Stacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3733-1001","authenticated-orcid":false,"given":"Christian","family":"Jobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9265-0283","authenticated-orcid":false,"given":"Timothy A.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-215X","authenticated-orcid":false,"given":"Renata","family":"Ferrarotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6669-6069","authenticated-orcid":false,"given":"Daniel J.","family":"McGrail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"1067_CR1","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856\u20131867 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1067_CR2","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915\u20131928 (2019).","journal-title":"Lancet"},{"key":"1067_CR3","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/S0140-6736(19)32539-5","volume":"394","author":"RL Ferris","year":"2019","unstructured":"Ferris, R. L. & Licitra, L. PD-1 immunotherapy for recurrent or metastatic HNSCC. Lancet 394, 1882\u20131884 (2019).","journal-title":"Lancet"},{"key":"1067_CR4","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1158\/1078-0432.CCR-22-2765","volume":"29","author":"S Wildsmith","year":"2023","unstructured":"Wildsmith, S. et al. Tumor mutational burden as a predictor of survival with durvalumab and\/or tremelimumab treatment in recurrent or metastatic head and neck squamous cell carcinoma. Clin. Cancer Res. 29, 2066\u20132074 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1067_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.it.2022.11.002","volume":"44","author":"C Villemin","year":"2023","unstructured":"Villemin, C. et al. The heightened importance of the microbiome in cancer immunotherapy. Trends Immunol. 44, 44\u201359 (2023).","journal-title":"Trends Immunol."},{"key":"1067_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104\u2013108 (2018).","journal-title":"Science"},{"key":"1067_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97\u2013103 (2018).","journal-title":"Science"},{"key":"1067_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91\u201397 (2018).","journal-title":"Science"},{"key":"1067_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.chom.2020.12.001","volume":"29","author":"AB Dohlman","year":"2021","unstructured":"Dohlman, A. B. et al. The cancer microbiome atlas: a pan-cancer comparative analysis to distinguish tissue-resident microbiota from contaminants. Cell Host Microbe 29, 281\u2013298 (2021).","journal-title":"Cell Host Microbe"},{"key":"1067_CR10","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/science.aah5043","volume":"357","author":"LT Geller","year":"2017","unstructured":"Geller, L. T. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156\u20131160 (2017).","journal-title":"Science"},{"key":"1067_CR11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41586-022-05435-0","volume":"611","author":"JL Galeano Ni\u00f1o","year":"2022","unstructured":"Galeano Ni\u00f1o, J. L. et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature 611, 810\u2013817 (2022).","journal-title":"Nature"},{"key":"1067_CR12","doi-asserted-by":"publisher","first-page":"100813","DOI":"10.1016\/j.neo.2022.100813","volume":"31","author":"C Michikawa","year":"2022","unstructured":"Michikawa, C. et al. Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). Neoplasia 31, 100813 (2022).","journal-title":"Neoplasia"},{"key":"1067_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","volume":"178","author":"E Riquelme","year":"2019","unstructured":"Riquelme, E. et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 178, 795\u2013806(2019).","journal-title":"Cell"},{"key":"1067_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1158\/2159-8290.CD-20-0263","volume":"11","author":"JJ Tsay","year":"2021","unstructured":"Tsay, J. J. et al. Lower airway dysbiosis affects lung cancer progression. Cancer Discov. 11, 293\u2013307 (2021).","journal-title":"Cancer Discov."},{"key":"1067_CR15","first-page":"560","volume":"9","author":"EM Quigley","year":"2013","unstructured":"Quigley, E. M. Gut bacteria in health and disease. Gastroenterol. Hepatol. (N. Y.) 9, 560\u2013569 (2013).","journal-title":"Gastroenterol. Hepatol. (N. Y.)"},{"key":"1067_CR16","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.cell.2012.01.035","volume":"148","author":"JC Clemente","year":"2012","unstructured":"Clemente, J. C., Ursell, L. K., Parfrey, L. W. & Knight, R. The impact of the gut microbiota on human health: an integrative view. Cell 148, 1258\u20131270 (2012).","journal-title":"Cell"},{"key":"1067_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2334\/josnusd.16-0856","volume":"59","author":"Y Yamashita","year":"2017","unstructured":"Yamashita, Y. & Takeshita, T. The oral microbiome and human health. J. Oral Sci. 59, 201\u2013206 (2017).","journal-title":"J. Oral Sci."},{"key":"1067_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tim.2022.08.010","volume":"31","author":"N Wang","year":"2023","unstructured":"Wang, N. & Fang, J. Y. Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer. Trends Microbiol. 31, 159\u2013172 (2023).","journal-title":"Trends Microbiol."},{"key":"1067_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41579-018-0129-6","volume":"17","author":"CA Brennan","year":"2019","unstructured":"Brennan, C. A. & Garrett, W. S. Fusobacterium nucleatum\u2014symbiont, opportunist and oncobacterium. Nat. Rev. Microbiol. 17, 156\u2013166 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"1067_CR20","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1126\/science.aal5240","volume":"358","author":"S Bullman","year":"2017","unstructured":"Bullman, S. et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358, 1443\u20131448 (2017).","journal-title":"Science"},{"key":"1067_CR21","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","volume":"170","author":"T Yu","year":"2017","unstructured":"Yu, T. et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170, 548\u2013563 (2017).","journal-title":"Cell"},{"key":"1067_CR22","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1158\/1078-0432.CCR-19-3977","volume":"26","author":"R Ferrarotto","year":"2020","unstructured":"Ferrarotto, R. et al. Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial results. Clin. Cancer Res. 26, 3211\u20133219 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1067_CR23","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/2159-8290.CD-20-1760","volume":"11","author":"AA Shamseddine","year":"2021","unstructured":"Shamseddine, A. A., Burman, B., Lee, N. Y., Zamarin, D. & Riaz, N. Tumor immunity and immunotherapy for HPV-related cancers. Cancer Discov. 11, 1896\u20131912 (2021).","journal-title":"Cancer Discov."},{"key":"1067_CR24","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1158\/1078-0432.CCR-06-2916","volume":"13","author":"S Peng","year":"2007","unstructured":"Peng, S. et al. HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin. Cancer Res. 13, 2479\u20132487 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1067_CR25","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.cell.2024.03.021","volume":"187","author":"TW Battaglia","year":"2024","unstructured":"Battaglia, T. W. et al. A pan-cancer analysis of the microbiome in metastatic cancer. Cell 187, 2324\u20132335(2024).","journal-title":"Cell"},{"key":"1067_CR26","doi-asserted-by":"publisher","first-page":"e01607","DOI":"10.1128\/mbio.01607-23","volume":"14","author":"A Gihawi","year":"2023","unstructured":"Gihawi, A. et al. Major data analysis errors invalidate cancer microbiome findings. mBio 14, e01607\u2013e01623 (2023).","journal-title":"mBio"},{"key":"1067_CR27","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41586-024-07656-x","volume":"631","author":"GD Poore","year":"2024","unstructured":"Poore, G. D. et al. Retraction Note: Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature 631, 694\u2013694 (2024).","journal-title":"Nature"},{"key":"1067_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-014-0087-z","volume":"12","author":"SJ Salter","year":"2014","unstructured":"Salter, S. J. et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol. 12, 87 (2014).","journal-title":"BMC Biol."},{"key":"1067_CR29","doi-asserted-by":"publisher","first-page":"e0059821","DOI":"10.1128\/mBio.00598-21","volume":"12","author":"R Dyrhovden","year":"2021","unstructured":"Dyrhovden, R. et al. Managing contamination and diverse bacterial loads in 16S rRNA deep sequencing of clinical samples: implications of the law of small numbers. mBio 12, e0059821 (2021).","journal-title":"mBio"},{"key":"1067_CR30","first-page":"01488","volume":"23","author":"A Elkrief","year":"2024","unstructured":"Elkrief, A. et al. Intratumoral Escherichia is associated with improved survival to single-agent immune checkpoint inhibition in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 01488 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1067_CR31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/bfgp\/elv054","volume":"15","author":"EG Seaby","year":"2016","unstructured":"Seaby, E. G., Pengelly, R. J. & Ennis, S. Exome sequencing explained: a practical guide to its clinical application. Brief. Funct. Genomics 15, 374\u2013384 (2016).","journal-title":"Brief. Funct. Genomics"},{"key":"1067_CR32","unstructured":"Cohen, J. Statistical Power Analysis for the Behavioral Sciences 2nd edn (Routledge or Lawrence Erlbaum Associates, 1988)."},{"key":"1067_CR33","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/jnci\/djac019","volume":"114","author":"F Poizeau","year":"2022","unstructured":"Poizeau, F. et al. The association between antibiotic use and outcome among metastatic melanoma patients receiving immunotherapy. J. Natl Cancer Inst. 114, 686\u2013694 (2022).","journal-title":"J. Natl Cancer Inst."},{"key":"1067_CR34","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/jnci\/djaa057","volume":"113","author":"JJ Mohiuddin","year":"2021","unstructured":"Mohiuddin, J. J. et al. Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy. J. Natl Cancer Inst. 113, 162\u2013170 (2021).","journal-title":"J. Natl Cancer Inst."},{"key":"1067_CR35","doi-asserted-by":"publisher","first-page":"e169823","DOI":"10.1172\/JCI169823","volume":"133","author":"C Valero","year":"2023","unstructured":"Valero, C. et al. Clinical\u2013genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma. J. Clin. Invest. 133, e169823 (2023).","journal-title":"J. Clin. Invest."},{"key":"1067_CR36","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chom.2023.04.010","volume":"31","author":"SS Jiang","year":"2023","unstructured":"Jiang, S. S. et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe 31, 781\u2013797(2023).","journal-title":"Cell Host Microbe"},{"key":"1067_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.oraloncology.2016.05.002","volume":"58","author":"RJ Davis","year":"2016","unstructured":"Davis, R. J., Van Waes, C. & Allen, C. T. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 58, 59\u201370 (2016).","journal-title":"Oral Oncol."},{"key":"1067_CR38","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.2015.61.1509","volume":"33","author":"RL Ferris","year":"2015","unstructured":"Ferris, R. L. Immunology and immunotherapy of head and neck cancer. J. Clin. Oncol. 33, 3293\u20133304 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1067_CR39","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","volume":"18","author":"KJ Harrington","year":"2017","unstructured":"Harrington, K. J. et al. Nivolumab versus standard, single-agent therapy of investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 18, 1104\u20131115 (2017).","journal-title":"Lancet Oncol."},{"key":"1067_CR40","unstructured":"Chan, T. A. et al. Tumor ecosystem and microbiome features associated with efficacy from avelumab-based multimodal therapy in a phase III randomized trial. Nat. Cancer (in the press)."},{"key":"1067_CR41","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1136\/gutjnl-2015-310101","volume":"65","author":"K Mima","year":"2016","unstructured":"Mima, K. et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 65, 1973\u20131980 (2016).","journal-title":"Gut"},{"key":"1067_CR42","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1001\/jamaoncol.2015.1377","volume":"1","author":"K Mima","year":"2015","unstructured":"Mima, K. et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 1, 653\u2013661 (2015).","journal-title":"JAMA Oncol."},{"key":"1067_CR43","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.3390\/ijms21176207","volume":"21","author":"N Fujiwara","year":"2020","unstructured":"Fujiwara, N. et al. Involvement of Fusobacterium species in oral cancer progression: a literature review including other types of cancer. Int. J. Mol. Sci. 21, 6207 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1067_CR44","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.annonc.2020.06.003","volume":"31","author":"G Serna","year":"2020","unstructured":"Serna, G. et al. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann. Oncol. 31, 1366\u20131375 (2020).","journal-title":"Ann. Oncol."},{"key":"1067_CR45","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nri3024","volume":"11","author":"A Mantovani","year":"2011","unstructured":"Mantovani, A., Cassatella, M. A., Costantini, C. & Jaillon, S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11, 519\u2013531 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"1067_CR46","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.cell.2023.02.032","volume":"186","author":"J Gungabeesoon","year":"2023","unstructured":"Gungabeesoon, J. et al. A neutrophil response linked to tumor control in immunotherapy. Cell 186, 1448\u20131464(2023).","journal-title":"Cell"},{"key":"1067_CR47","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.cell.2023.03.007","volume":"186","author":"D Hirschhorn","year":"2023","unstructured":"Hirschhorn, D. et al. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell 186, 1432\u20131447(2023).","journal-title":"Cell"},{"key":"1067_CR48","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1158\/2159-8290.CD-17-1134","volume":"8","author":"S Pushalkar","year":"2018","unstructured":"Pushalkar, S. et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 8, 403\u2013416 (2018).","journal-title":"Cancer Discov."},{"key":"1067_CR49","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.12.040","volume":"176","author":"C Jin","year":"2019","unstructured":"Jin, C. et al. Commensal microbiota promote lung cancer development via \u03b3\u03b4 T cells. Cell 176, 998\u20131013 (2019).","journal-title":"Cell"},{"key":"1067_CR50","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","volume":"5","author":"DJ Pinato","year":"2019","unstructured":"Pinato, D. J. et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 5, 1774\u20131778 (2019).","journal-title":"JAMA Oncol."},{"key":"1067_CR51","doi-asserted-by":"publisher","first-page":"e1665973","DOI":"10.1080\/2162402X.2019.1665973","volume":"8","author":"XZ Huang","year":"2019","unstructured":"Huang, X. Z. et al. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients. Oncoimmunology 8, e1665973 (2019).","journal-title":"Oncoimmunology"},{"key":"1067_CR52","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","volume":"29","author":"L Derosa","year":"2018","unstructured":"Derosa, L. et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann. Oncol. 29, 1437\u20131444 (2018).","journal-title":"Ann. Oncol."},{"key":"1067_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082342","volume":"15","author":"S Preissner","year":"2023","unstructured":"Preissner, S., Heiland, M., Preissner, R., Wirth, M. & Wollenberg, B. Antibiotics significantly decrease the survival of head and neck carcinoma patients with immunotherapy: a real-world analysis of more than 3000 cases. Cancers (Basel) 15, 2342 (2023).","journal-title":"Cancers (Basel)"},{"key":"1067_CR54","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000533860","volume":"102","author":"R Ueta","year":"2024","unstructured":"Ueta, R. et al. Antibiotics may interfere with nivolumab efficacy in patients with head and neck squamous cell carcinoma. Oncology 102, 252\u2013259 (2024).","journal-title":"Oncology"},{"key":"1067_CR55","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1007\/s10147-025-02797-z","volume":"30","author":"K Minohara","year":"2025","unstructured":"Minohara, K. et al. Impact of medications on the efficacy of immune checkpoint inhibitors in patients with recurrent or metastatic head and neck cancer. Int. J. Clin. Oncol. 30, 1572\u20131581 (2025).","journal-title":"Int. J. Clin. Oncol."},{"key":"1067_CR56","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345\u2013362 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1067_CR57","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail, D. J. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. 32, 661\u2013672 (2021).","journal-title":"Ann. Oncol."},{"key":"1067_CR58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","volume":"393","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri, R. et al. Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer. N. Engl. J. Med. 393, 37\u201350 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1067_CR59","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ame2.12257","volume":"5","author":"J Guo","year":"2022","unstructured":"Guo, J. et al. Characteristics of gut microbiota in representative mice strains: implications for biological research. Animal Model. Exp. Med. 5, 337\u2013349 (2022).","journal-title":"Animal Model. Exp. Med."},{"key":"1067_CR60","doi-asserted-by":"publisher","first-page":"4.1.1","DOI":"10.1002\/0471142735.im0401s113","volume":"113","author":"K Laky","year":"2016","unstructured":"Laky, K. & Kruisbeek, A. M. In vivo depletion of T lymphocytes. Curr. Protoc. Immunol. 113, 4.1.1\u20134.1.9 (2016).","journal-title":"Curr. Protoc. Immunol."},{"key":"1067_CR61","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/php.13040","volume":"95","author":"RWT Davis","year":"2019","unstructured":"Davis, R. W. T. et al. Luminol chemiluminescence reports photodynamic therapy-generated neutrophil activity in vivo and serves as a biomarker of therapeutic efficacy. Photochem. Photobiol. 95, 430\u2013438 (2019).","journal-title":"Photochem. Photobiol."},{"key":"1067_CR62","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525\u2013527 (2016).","journal-title":"Nat. Biotechnol."},{"key":"1067_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1092-z","volume":"17","author":"Y \u015eenbabao\u011flu","year":"2016","unstructured":"\u015eenbabao\u011flu, Y. et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 17, 231 (2016).","journal-title":"Genome Biol."},{"key":"1067_CR64","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782\u2013795 (2013).","journal-title":"Immunity"},{"key":"1067_CR65","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","volume":"13","author":"BJ Callahan","year":"2016","unstructured":"Callahan, B. J. et al. DADA2: high-resolution sample inference from Illumina amplicon data. Nat. Methods 13, 581\u2013583 (2016).","journal-title":"Nat. Methods"},{"key":"1067_CR66","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1128\/JB.00542-10","volume":"192","author":"FE Dewhirst","year":"2010","unstructured":"Dewhirst, F. E. et al. The human oral microbiome. J. Bacteriol. 192, 5002\u20135017 (2010).","journal-title":"J. Bacteriol."},{"key":"1067_CR67","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.abj6987","volume":"376","author":"S Nurk","year":"2022","unstructured":"Nurk, S. et al. The complete sequence of a human genome. Science 376, 44\u201353 (2022).","journal-title":"Science"},{"key":"1067_CR68","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"1067_CR69","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1200\/EDBK_199697","volume":"38","author":"W Lydiatt","year":"2018","unstructured":"Lydiatt, W., O\u2019Sullivan, B. & Patel, S. Major changes in head and neck staging for 2018. Am. Soc. Clin. Oncol. Educ. Book 38, 505\u2013514 (2018).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"1067_CR70","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.oraloncology.2016.10.009","volume":"62","author":"H Mirghani","year":"2016","unstructured":"Mirghani, H. et al. Diagnosis of HPV driven oropharyngeal cancers: comparing p16 based algorithms with the RNAscope HPV-test. Oral Oncol. 62, 101\u2013108 (2016).","journal-title":"Oral Oncol."},{"key":"1067_CR71","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"Seiwert, T. Y. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17, 956\u2013965 (2016).","journal-title":"Lancet Oncol."},{"key":"1067_CR72","doi-asserted-by":"publisher","unstructured":"Benjamin, D. et al. Calling somatic SNVs and indels with Mutect2. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/861054 (2019).","DOI":"10.1101\/861054"},{"key":"1067_CR73","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1158\/0008-5472.CAN-17-0337","volume":"77","author":"JT Robinson","year":"2017","unstructured":"Robinson, J. T., Thorvaldsd\u00f3ttir, H., Wenger, A. M., Zehir, A. & Mesirov, J. P. Variant review with the Integrative Genomics Viewer. Cancer Res. 77, e31\u2013e34 (2017).","journal-title":"Cancer Res."},{"key":"1067_CR74","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41588-020-0592-7","volume":"52","author":"DJH Shih","year":"2020","unstructured":"Shih, D. J. H. et al. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat. Genet. 52, 371\u2013377 (2020).","journal-title":"Nat. Genet."},{"key":"1067_CR75","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1093\/bioinformatics\/bty501","volume":"34","author":"MA Walker","year":"2018","unstructured":"Walker, M. A. et al. GATK PathSeq: a customizable computational tool for the discovery and identification of microbial sequences in libraries from eukaryotic hosts. Bioinformatics 34, 4287\u20134289 (2018).","journal-title":"Bioinformatics"},{"key":"1067_CR76","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00354-23","volume":"9","author":"PD Schloss","year":"2024","unstructured":"Schloss, P. D. Rarefaction is currently the best approach to control for uneven sequencing effort in amplicon sequence analyses. mSphere 9, e0035423 (2024).","journal-title":"mSphere"},{"key":"1067_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00011","volume":"1","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 1, 1\u201316 (2017).","journal-title":"JCO Precis. Oncol."},{"key":"1067_CR78","first-page":"D863","volume":"48","author":"SH Liu","year":"2020","unstructured":"Liu, S. H. et al. DriverDBv3: a multi-omics database for cancer driver gene research. Nucleic Acids Res. 48, D863\u2013D870 (2020).","journal-title":"Nucleic Acids Res."},{"key":"1067_CR79","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1067_CR80","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"1067_CR81","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41522-017-0040-3","volume":"3","author":"JL Drewes","year":"2017","unstructured":"Drewes, J. L. et al. High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia. Biofilms Microbiomes 3, 34 (2017).","journal-title":"Biofilms Microbiomes"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01067-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01067-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01067-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:02:37Z","timestamp":1769785357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01067-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-01067-1","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"9 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.A.C. is a cofounder of Gritstone Oncology and holds equity. T.A.C. holds equity in An2H. T.A.C. acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H and Eisai. T.A.C. has served as an advisor for Bristol-Myers, MedImmune, Squibb, Illumina, Eisai, AstraZeneca and An2H. T.A.C. is an inventor on intellectual property held by Memorial Sloan Kettering Cancer Center on using TMB to predict immunotherapy response, with a pending patent, which has been licensed to PGDx. E.J.S. consults for Siren Biotechnology and has immunotherapy patent applications under option to license agreements with iOncologi. N.G. reports grants or contracts and personal or consulting fees from Regeneron Pharmaceuticals, personal or consulting fees from DragonFly Therapeutics, Intuitive Surgical, Merck, Replimune and Sanofi\/Genzyme US Companies and support for other professional activities from PDS Biotechnology Corporation outside the submitted work. R.F. reports consulting or advisory roles for Regeneron, Sanofi, Ayala Pharmaceuticals, Prelude Therapeutics, Elevar Therapeutics, G1 Therapeutics, Guidepoint, Expert Connect, Remix, Eisai and Bioatlas in the past 24\u2009months and research funds from Prelude, Ayala, Merck, Genentech, Pfizer, Rakuten, Nanobiotix, EMD Serono, ISA, Viracta and Gilead in the past 24\u2009months. D.J.M. holds intellectual property for transcriptional signatures to predict response to ICB. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}